Headline. 413-A East Main Street; Charlottesville, VA 22902; US: +1 800 698 9101; International: +1 434 293 9100 Get news for AMEX companies quoted on the stock market, press releases, financial disclosures and multimedia content, for investment community, individual investors and the general public. The New York-based company … BRIEF-Actinium Pharmaceuticals Says Actimab-A Being Studied In A Phase 1 Combination With Bcl-2 Inhibitor In Patients With Relapsed Or Refractory AML 26th Feb '20 News BRIEF-Actinium Presents Positive Findings From Mid-Point Analysis Of Pivotal Sierra Trial Of Iomab-B At 2020 Transplantation & Cellular Therapy Meetings Of ASTCT And CIBMTR Together, we can accelerate the development of pharmaceuticals using actinium-225 and bring this material to patients in need of life-saving cancer therapy. MORE. Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Get Actinium Pharmaceuticals Inc (ATNM:NYSE American) real-time stock quotes, news, price and financial information from CNBC. Actinium Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ATNM: Get the latest Actinium Pharmaceuticals stock price and detailed information including ATNM news, historical charts and realtime prices. The company report on June 19, 2020 that Actinium Pharmaceuticals, Inc. Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies ... SIERRA: Pivotal Phase 3 Clinical Trial of Iomab-B. Weiter > Weiter > < Zurück < Zurück. ATNM lost -$2.59 per share in the over the last 12 months. NEW YORK (AP) — Actinium Pharmaceuticals Inc. (ATNM) on Friday reported a loss of $5.3 million in its first quarter. Actinium Pharmaceuticals News Headlines $7.01-0.17 (-2.37 %) (As of 05/13/2021 12:00 AM ET) Add. View real-time stock prices and stock quotes for a full financial overview. About Actinium Pharmaceuticals Inc. Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. PR Newswire. Contact Us. Nymox Pharmaceutical (NASDAQ:NYMX) trades 15.9% down premarket after entering into a definitive agreement with institutional investors in a … Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference. Actinium, Astellas Collaborate on Actinium-225 Based Targeted Radiotherapies Actinium Pharmaceuticals, Inc. has announced the research collaboration with Astellas Pharma… by News Release Actinium (ACM) Trading Down 11% This Week Mon, May 17, 2021 6:54 PM americanbankingnews. actinium pharmaceuticals inc (atnm): * actinium announces completion of enrollment of second dose cohort in actimab-a venetoclax combination trial for patients with r/r aml. Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Astellas Announces a Research Collaboration with Actinium for Molecular Targeted Radiotherapy. Wire. The Actinium Pharmaceuticals, Inc stock price gained 2.16% on the last trading day (Friday, 21st May 2021), rising from $7.87 to $8.04. Email. View which stocks have been most impacted by COVID-19. Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know by Zacks Equity Research Published on December 23,2020 Actinium Pharmaceuticals (ATNM) … Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage biopharmaceutical company. A clinical-stage pharmaceutical company, Actinium Pharmaceuticals, Inc. is developing Antibody Radiation-Conjugates. Share . Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Ranked in Earnings Gainer and 1 other category Data delayed 15 minutes. Receive the latest news, events and updates! Productivity increased at an annual rate of 5.4% in the first quarter, recovering from a 3.8% rate of decline in the fourth quarter of last year, the Labor Department reported Thursday. Find real-time ATNM - Actinium Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) has been completed. Actinium Pharmaceuticals News. Email Sign Up. NEWS -- Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform. WASHINGTON — U.S. productivity posted a sharp rebound between January and March after falling in the previous quarter. Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARC’s or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Receive the latest news, events and updates! Contact U.S. News Best Stocks. Company profile page for Actinium Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Actinium Pharmaceuticals has received 63.43% “outperform” votes from our community. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $30.57 average price target, implying a 25.5% upside from current levels. Compare. H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) on January 13 and set a price target of $65.00.The company’s shares closed last Tuesday at $8.06. BRIEF-Actinium Pharmaceuticals Says Actimab-A Being Studied In A Phase 1 Combination With Bcl-2 Inhibitor In Patients With Relapsed Or Refractory AML 26th Feb '20 News BRIEF-Actinium Presents Positive Findings From Mid-Point Analysis Of Pivotal Sierra Trial Of Iomab-B At 2020 Transplantation & Cellular Therapy Meetings Of ASTCT And CIBMTR Shares opened today at $8.04. Officers and employees of William Blair or its affiliates (other than research analysts) may have a financial interest in securities of Actinium Pharmaceuticals, Inc. 52-Week Range. Actinium Pharmaceuticals, Inc. is or was, within the last 12 months, an investment banking client of William Blair & Company and/or one or more of its affiliates. News. TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope. Announces Closing Of $31.6 Million Public Offering, Including Full Exercise Of The Underwriters' Option To Purchase Additional Shares … Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results. Actinium Pharmaceuticals (ATNM) closed at $0.24 in the latest trading session, marking a +1.04% move from the prior day. In 1939, Perey noted that actinium she had obtained by fractional precipitation of uranium ore emitted an unexpected type of radiation. William Blair analyst A. Hsieh anticipates that the biotechnology company will post earnings of ($0.29) per share for the quarter. The following article is sponsored by Actinium Pharmaceuticals, Inc. NEW YORK (AP) _ Actinium Pharmaceuticals Inc. (ATNM) on Friday reported a loss of $5.3 million in its first quarter. Find out why Actinium Pharmaceuticals's (ATNM) news sentiment is more negative in … NEW YORK, March 25, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in... 1 month ago - PRNewsWire The question becomes, what are the chances the stock … It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates (ARCs), … On the Street’s front, the average 12-month analyst price target for the stock is $57.00, marking a 608.96% potential upside from current levels. Actinium Pharmaceuticals Inc. (AMEX: ATNM) is 21.79% higher on its value in year-to-date trading and has touched a low of $4.71 and a high of $19.47 in the current 52-week trading range. We cover the latest Actinium Pharmaceuticals headlines and breaking news impacting Actinium Pharmaceuticals stock performance. ATNM | Complete Actinium Pharmaceuticals Inc. stock news by MarketWatch. View today's stock price, news and analysis for Actinium Pharmaceuticals Inc. (ATNM). Their platform is … 01/20 07:00. Announces Closing of $25.0 Million Public Offering. View detailed financial information, real-time news, videos, quotes and analysis on Actinium Pharmaceuticals, Inc. (AMEX:ATNM). In a report issued on April 26, Credit Suisse also initiated coverage with a Hold rating on the stock with a $190.00 price target. von 6. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) has been completed. on May 17th. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on the Mediterranean, which is … Actinium Pharmaceuticals NYSE Updated May 21, 2021 8:00 PM. Actinium Pharmaceuticals (NYSE: ATNM) Trending Biopharma Stock. SA Breaking News. Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other... Company Analysis and Financial Data Status Unless specified all financial data is based on a yearly period but updated quarterly. Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates (ARCs), … The cancer drug developer posted revenue of $622,000 in the period. All news about ACTINIUM PHARMACEUTICALS, INC. 04/01: ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Actinium Pharm.. MT Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Nektar Therapeutics, and Beyondspring. The panel discussion included Steve O’Loughlin, CFO of Actinium Pharmaceuticals Inc (NYSE: ATNM), Bill Williams, ... Everything you need to know about the latest SPAC news. BMT or HSCT (Hematopoietic Stem Cell Transplantation) is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient. Actinium Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Actinium … Explore commentary on Actinium Pharmaceuticals, … MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. von 6. Contact Us. Currently, the analyst consensus on Alexion Pharmaceuticals is a Hold with an average price target of $175.67, implying a 4.1% upside from current levels. Actinium Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Email Sign Up. Find the latest Actinium Pharmaceuticals, Inc. (ATNM) stock quote, history, news and other vital information to help you with your stock trading and investing. Read More. Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (ATNM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Actinium Pharmaceuticals is down -5.35% in midday trading to $7.61. 13.59 million Float (est.) Post transaction, HDFC Mutual Fund (HDFC MF) has increased its total stake in GE Shipping to 7.23% from 5.13% stake earlier. NEW YORK, March 31, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on the Mediterranean, which is being held virtually April 6 – 9, 2021, where it will feature its Iomab-ACT program. Vancouver, BC, December 17, 2020--TRIUMF, Canada's particle accelerator centre, announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next … It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the H.C. Wainwright (HCW) Global Life … $5.22 $19.47. Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly 01:07pm, Tuesday, 06'th Apr 2021. Actinium Pharmaceuticals, I Find the latest news headlines from Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (ATNM) at Nasdaq.com. The New York-based company said it had a loss of 29 cents per share. Ranked in Earnings Gainer and 1 other category Data delayed 15 minutes. $6.92 $7.28. So, it contains more downside volatility than upside When share has dropped more than 10% since it's last Earning release, it tends to over react to minor good news and recover some drops if not all. Zacks News for ATNM Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know 12/23/20-4:45PM EST Zacks Actinium Pharmaceuticals Inc ATNM ... Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Ownership Executive News. Actinium Pharmaceuticals, Inc. Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity PR Newswire - PRF - Mon Nov 23, 6:00AM CST So it had a cash runway of about 2.9 years from December 2020. Average Volume342,816 shs. Stock analysis for Actinium Pharmaceuticals Inc (ATNM:NYSEAmerican) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Actinium Pharmaceuticals (NYSE:ATNM) is a clinical stage biotech developing treatments in the growing field of targeted radiotherapies. ATNM 8.04 0.17 (2.16%). May 17, 2021. On a consolidated basis, … When Actinium Pharmaceuticals last reported its balance sheet in December 2020, it had zero debt and cash worth US$64m. The information contained in this article in no way represents investment advice or opinion on … Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) – Analysts at William Blair issued their Q1 2022 EPS estimates for Actinium Pharmaceuticals in a research report issued on Monday, May 17th. Contact. Actinium Pharmaceuticals Inc ATNM Vitals. ATNM: Get the latest Actinium Pharmaceuticals stock price and detailed information including ATNM news, historical charts and realtime prices. Actinium Pharmaceuticals' stock was trading at $0.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATNM stock has increased by 3,287.5% and is now trading at $8.13. View which stocks have been most impacted by COVID-19. Sign Up Now Avinash Desai has joined the company as Executive Vice President of Clinical Development, Operations and Medical Affairs (news … What this means: InvestorsObserver gives Actinium Pharmaceuticals Inc (ATNM) an overall rank of 45, which is below average. ATNM, Actinium Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Actinium Pharmaceuticals Stock Quote: ATNM Stock News, Quotes, Analysis | Investors.com ATNM Actinium Pharmaceuticals Inc Latest News. When share has gained more than 10% since it's last Earning release, it tends to over react to minor bad news and give up some gains if not all. Actinium Pharmaceuticals, Inc stock price up 2.16% on Friday (Updated on May 21, 2021) Buy candidate since 2021-05-20 Gain 2.16% PDF . Actinium Pharmaceuticals Estimiated After-Hype Price Volatility In the context of predicting Actinium Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Actinium Pharmaceuticals' historical news … NEW YORK, June 16, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the pricing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.325 per share of common stock (or common stock equivalent). Read More. Over the past year the S&P 500 is up 58.16% while ATNM has risen 49.22%. ATNM | Complete Actinium Pharmaceuticals Inc. stock news by MarketWatch. Company Name: Actinium Pharmaceuticals Inc., Stock Symbol: ATNM, Industry: Biotechs, Total Posts: 2565, Last Post: 5/21/2021 8:49:04 AM According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 41.6% and a 62.8% success rate. Most relevant news about ACTINIUM PHARMACEUTICALS, INC. 05/14: ACTINIUM: Q1 Earnings Snapshot: AQ. Actinium Pharmaceuticals News: This is the News-site for the company Actinium Pharmaceuticals on Markets Insider Since then, ATNM shares have increased by 3,250.0% and is now trading at $8.04. ... News / Therapeutic Area News. The question becomes, what are the chances the stock … Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. 12.78 million shares. Actinium Pharmaceuticals Inc. [AMEX: ATNM] jumped around 0.03 points on Friday, while shares priced at $0.53 at the close of the session, up 7.45%. Actinium (CURRENCY:ACM) traded 0.8% lower against the US dollar during the 1-day period ending at 19:00 PM E.T. View real-time stock prices and stock quotes for a full financial overview. The following article is sponsored by Actinium Pharmaceuticals, Inc. Pantginis covers the Healthcare sector, … About Actinium Pharmaceuticals Inc. Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. MORE. PR … According to TipRanks.com, Pantginis is a top 25 analyst with an average return of 46.6% and a 66.8% success rate. TerraPower and POINT Biopharma signed a supply agreement for the medical radioisotope actinium-225. ATNM Actinium Pharmaceuticals $7.57 / -0.23 (-2.95%) 03/25/21 Actinium Pharmaceuticals completes enrollment of second cohort in AML trial 03/24/21 Actinium Pharmaceuticals begins patient enrollment in Iomab-ACT trial 03/03/21 Actinium Pharmaceuticals appoints Mark Kubik as Chief Business Office 01/13/21 Actinium Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Today's Range. Why we like ATNM shares at their current price: Tiny float Proprietary, patented technology Late-stage clinical trial So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is … Current price $10.84 per share (Friday’s close) Outstanding shares (est.) Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with … Actinium Pharmaceuticals, Inc. is trading on the NYSE American under the ticker ATNM. (Add your “underperform” vote.) Sign Up Now A rank of 45 means that 55% of stocks appear more favorable to our system. Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML Mar 25, 2021 Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy Mar 24, 2021 Actinium (ATNM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? 10-Q: ACTINIUM PHARMACEUTICALS, INC. Email Sign Up. Weiter > Weiter > 31.03.21 - PR Newswire Actinium to Participate in the Cell & Gene Meeting on the Mediterranean. View today's stock price, news and analysis for Actinium Pharmaceuticals Inc. (ATNM). Actinium Pharmaceuticals Reports 100% Remission Rate in Cohort of Phase 1 Study of Actimab-A CLAG; Shares Rise 10% 12:42PM ET 11/04/2020 MT Newswires. One Actinium coin can now be purchased for $0.0363 or 0.00000083 BTC on popular exchanges. Find the latest Actinium Pharmaceuticals, Inc. (ATNM) stock quote, history, news and other vital information to help you with your stock trading and investing. William Blair also issued estimates for Actinium Pharmaceuticals… Volume178,825 shs. Actinium News. Mark Kubik has joined the company as Chief Business Officer (news posted on March 3 2021). Actinium Pharmaceuticals (ATNM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? Is (ATNM) Outperforming Other Medical Stocks This Year? NEW YORK , March 31, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on the Mediterranean, which is being held virtually April 6 – 9, 2021, where it will feature its Iomab-ACT program. Actinium Pharmaceuticals Iomab-B: Innovative Cancer Approach And Research Actinium’s novel approach may benefit patients with a broad range of hematologic malignancies, including acute … Earlier, he served as Vice President and Chief Financial Officer at Emisphere Technologies from 1991 to 1992 and as General Partner and Chief Financial Officer of CW Group Inc. Mr. Steinhart is a Member of the Board of Directors of Actinium Pharmaceuticals where he is Chairman of the Audit Committee and a member of the Compensation Committee. Get the latest Actinium Pharmaceuticals Inc (ATNM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Actinium Pharmaceuticals, Inc Stock News NYSE:ATNM. Actinium Pharmaceuticals stock news, updates & related news. Actinium Pharmaceuticals' stock was trading at $0.24 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. As of July 10, 2020, It … Mary Mei Chen has joined the company as Vice President of Clinical Development (news posted on December 1 2020). News / Therapeutic Area News.
Nicole Paige Brooks Instagram, Mini Cooper Deutschland, Most Popular Jewelry 2021, Hugo Sánchez Champions League, Marakkar Arabikadalinte Simham Full Movie Dailymotion, Is Your Immune System Weaker After A Vaccine, Norovirus 2020 Outbreak Map, Erie County Ohio Weather, Sierra Marine Contact, Hudson, Nh Standoff 2021, Wellhead Protection Area Map, Where Is Richard Dunwoody Now,